The confidentiality of the information contained in the administrative file of a fixed-dose combination medicinal product and the need for an opinion on relevance in order to lift such level of protection
[et_pb_section bb_built=”1″ _builder_version=”3.19.5″][et_pb_row][et_pb_column type=”2_5″][et_pb_image _builder_version=”3.19.5″ src=”https://desarrollo.vidalquadrasramon.com/wp-content/uploads/2021/02/VQR_LAW_NEW34.jpg” /][/et_pb_column][et_pb_column type=”3_5″][et_pb_post_title _builder_version=”3.19.5″ comments=”off” featured_image=”off” /][et_pb_text _builder_version=”3.19.5″] In some recent and interesting proceedings, a Central Contentious Administrative Court in Madrid refused to provide further information contained in the administrative files of two pharmaceutical companies (codefendants) and hence the confidential information could not be obtained that was included in the ...
